JPWO2021016388A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021016388A5 JPWO2021016388A5 JP2022504701A JP2022504701A JPWO2021016388A5 JP WO2021016388 A5 JPWO2021016388 A5 JP WO2021016388A5 JP 2022504701 A JP2022504701 A JP 2022504701A JP 2022504701 A JP2022504701 A JP 2022504701A JP WO2021016388 A5 JPWO2021016388 A5 JP WO2021016388A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- pharmaceutically acceptable
- acceptable salt
- polymorph
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962877788P | 2019-07-23 | 2019-07-23 | |
| US62/877,788 | 2019-07-23 | ||
| PCT/US2020/043132 WO2021016388A1 (en) | 2019-07-23 | 2020-07-22 | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022541644A JP2022541644A (ja) | 2022-09-26 |
| JPWO2021016388A5 true JPWO2021016388A5 (https=) | 2023-09-26 |
| JP2022541644A5 JP2022541644A5 (https=) | 2023-09-26 |
| JP7680999B2 JP7680999B2 (ja) | 2025-05-21 |
Family
ID=74192704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022504701A Active JP7680999B2 (ja) | 2019-07-23 | 2020-07-22 | サイクリン依存性キナーゼ７のインヒビターおよびそれらの使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230242534A9 (https=) |
| EP (1) | EP4003335A4 (https=) |
| JP (1) | JP7680999B2 (https=) |
| CN (1) | CN114401719A (https=) |
| AU (1) | AU2020319005B2 (https=) |
| CA (1) | CA3147106A1 (https=) |
| WO (1) | WO2021016388A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015371251B2 (en) | 2014-12-23 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| HK1246645A1 (zh) | 2015-03-27 | 2018-09-14 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
| US12187701B2 (en) | 2018-06-25 | 2025-01-07 | Dana-Farber Cancer Institute, Inc. | Taire family kinase inhibitors and uses thereof |
| JP7660063B2 (ja) | 2018-12-28 | 2025-04-10 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | サイクリン依存性キナーゼ７のインヒビターおよびそれらの使用 |
| US20230114207A1 (en) * | 2019-12-24 | 2023-04-13 | Dana-Farber Cancer Institute, Inc. | The combination of cyclin dependent kinase 7 inhibitor and immunotherapy for treatment of cancer |
| KR20240035820A (ko) | 2021-07-09 | 2024-03-18 | 플렉시움 인코포레이티드 | Ikzf2를 조절하는 아릴 화합물 및 약학 조성물 |
| WO2023107705A1 (en) | 2021-12-10 | 2023-06-15 | Incyte Corporation | Bicyclic amines as cdk12 inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA81790C2 (uk) * | 2002-12-19 | 2008-02-11 | Фармация Италия С.П.А. | Заміщені піролопіразольні похідні як інгібітори кінази |
| ES2661883T3 (es) * | 2012-07-09 | 2018-04-04 | Novartis Ag | Biomarcadores asociados con inhibidores de CDK |
| AU2015371251B2 (en) * | 2014-12-23 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| HK1246645A1 (zh) * | 2015-03-27 | 2018-09-14 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
| US10702527B2 (en) * | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
-
2020
- 2020-07-22 EP EP20843441.5A patent/EP4003335A4/en active Pending
- 2020-07-22 CA CA3147106A patent/CA3147106A1/en active Pending
- 2020-07-22 CN CN202080052924.XA patent/CN114401719A/zh active Pending
- 2020-07-22 WO PCT/US2020/043132 patent/WO2021016388A1/en not_active Ceased
- 2020-07-22 JP JP2022504701A patent/JP7680999B2/ja active Active
- 2020-07-22 AU AU2020319005A patent/AU2020319005B2/en active Active
- 2020-07-22 US US17/628,794 patent/US20230242534A9/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019129727A (ru) | Применения пиримидопиримидинонов в качестве ингибиторов sik | |
| JP2020509022A5 (https=) | ||
| CA2793311C (en) | Modulators of hec1 activity and methods therefor | |
| JP2018522866A5 (https=) | ||
| JP2015531773A5 (https=) | ||
| JP2020516616A5 (https=) | ||
| JPWO2021143701A5 (https=) | ||
| TW201021798A (en) | Amide acetate derivative having inhibitory activity on endothelial lipase | |
| JP2017537886A5 (https=) | ||
| JPWO2021016388A5 (https=) | ||
| JP2021513543A5 (https=) | ||
| JPWO2021133896A5 (https=) | ||
| US20080287390A1 (en) | Pyrazolidinol compounds | |
| JP6505095B2 (ja) | Ｔｃｒ−ｎｃｋ相互作用の阻害剤としての、アルコキシドによって置換されたクロメン誘導体 | |
| JPWO2020140098A5 (https=) | ||
| JPWO2022029138A5 (https=) | ||
| JP2021527692A (ja) | Ｏａｔ３の阻害剤を用いた神経変性に関連する状態の処置方法 | |
| RU2093155C1 (ru) | Применение 5-[2-хлор-1-гидроксиэтил]-4-метилтиазола для снижения поражения нейронов, подавления конвульсий и снижения двигательной активности | |
| US12570685B2 (en) | 2-methoxyestradiol derivatives and medical uses thereof | |
| RU2024116813A (ru) | Гетероциклическое соединение, имеющее противоопухолевую активность, и его применение | |
| CA3060481C (en) | Compounds for the treatment of epilepsy, neurodegenerative disorders and other cns disorders | |
| RU2025117683A (ru) | Соединение нафтиламида, а также способ его получения и применения | |
| RU2024129167A (ru) | Агонисты gpr120 для лечения воспалительных заболеваний кишечника | |
| JP2024512710A (ja) | ５－ベンジルイミダゾール類化合物並びにその調製方法及び用途 | |
| WO2021042194A1 (pt) | Composto derivado de quinolina, uso de um composto, composição, e, método para o tratamento ou profilaxia de uma condição causada por um parasito do sangue |